Format

Send to

Choose Destination
Nat Rev Cancer. 2012 Jul 24;12(8):513-26. doi: 10.1038/nrc3317.

Pushing the limits of targeted therapy in chronic myeloid leukaemia.

Author information

1
Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, Utah 84112, USA. Thomas.OHare@hci.utah.edu

Erratum in

  • Nat Rev Cancer. 2012 Dec;12(12):886.

Abstract

Tyrosine kinase inhibitor (TKI) therapy targeting the BCR-ABL1 kinase is effective against chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual disease (MRD) is thought to reside in TKI-insensitive leukaemia stem cells (LSCs) that are not fully addicted to BCR-ABL1. Recent conceptual advances in both CML biology and therapeutic intervention have increased the potential for the elimination of CML cells, including LSCs, through simultaneous inhibition of BCR-ABL1 and other newly identified, crucial targets.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00574873 NCT00827138 NCT01207440.

PMID:
22825216
DOI:
10.1038/nrc3317
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center